Titre :
  • p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Auteur : Di Leo, Angelo ; Tanner, M ; Desmedt, Christine ; Paesmans, Marianne ; Cardoso, Fatima ; Durbecq, Virginie ; Chan, S ; Perren, Thimothy J. ; Aapro, Matti ; Sotiriou, Christos ; Piccart-Gebhart, Martine ; Larsimont, Denis ; Isola, Jorma ; TAX 303 translational study team
Informations sur la publication : Annals of oncology, 18, 6, (page 997-1003)
Statut de publication : Publié, 2007-06
Sujet CREF : Sciences bio-médicales et agricoles
Cancérologie
Médecine pathologie humaine
Mots-clés : Cytotoxics
Molecular markers
Topoisomerase II alpha
Mots-clés MeSH : Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- genetics
Breast Neoplasms -- pathology
Chromatography, High Pressure Liquid
DNA Primers
DNA, Neoplasm -- genetics
DNA, Neoplasm -- isolation & purification
Doxorubicin -- therapeutic use
Genes, p53
Mutation
Predictive Value of Tests
Probability
Protein Biosynthesis
Taxoids -- therapeutic use
Note : Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0923-7534 
info:doi/10.1093/annonc/mdm075
info:pii/mdm075
info:pmid/17369602